Viridian Therapeutics Inc (VRDN): Next-Year EPS Estimate 35.80%
As of 2026-06-11, Viridian Therapeutics Inc (VRDN) has a next-year EPS growth estimate of 35.80%.
On 2026-05-17, analyst consensus for VRDN's next-year EPS growth shifted from 36.01% to 35.80% — a negative change of 0.21 percentage points. The revised estimate has been sustained across 20 subsequent trading sessions. Current-year growth is projected at -13.60%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 35.80%
- EPS growth this year
- -13.60%
- EPS next quarter (est)
- -$1.03
- Last price
- $16.14
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-11 | 35.80% | -13.60% | -$1.03 | $16.14 |
| 2026-06-10 | 35.80% | -13.60% | -$1.03 | $15.77 |
| 2026-06-09 | 35.80% | -13.60% | -$1.03 | $16.31 |
| 2026-06-08 | 35.80% | -13.60% | -$1.03 | $15.73 |
| 2026-06-07 | 35.80% | -13.60% | -$1.03 | $15.78 |
| 2026-06-04 | 35.80% | -13.60% | -$1.03 | $16.57 |
| 2026-06-03 | 35.80% | -13.60% | -$1.03 | $16.35 |
| 2026-06-02 | 35.80% | -13.60% | -$1.03 | $15.87 |
| 2026-06-01 | 35.80% | -13.60% | -$1.03 | $16.96 |
| 2026-05-31 | 35.80% | -13.60% | -$1.03 | $17.62 |
| 2026-05-28 | 35.80% | -13.60% | -$1.03 | $17.45 |
| 2026-05-27 | 35.80% | -13.60% | -$1.03 | $17.26 |
| 2026-05-26 | 35.80% | -13.60% | -$1.03 | $17.00 |
| 2026-05-25 | 35.80% | -13.60% | -$1.03 | $17.24 |
| 2026-05-24 | 35.80% | -13.60% | -$1.03 | $17.24 |
| 2026-05-21 | 35.80% | -13.60% | -$1.03 | $17.69 |
| 2026-05-20 | 35.80% | -13.60% | -$1.03 | $17.63 |
| 2026-05-19 | 35.80% | -13.60% | -$1.03 | $15.97 |
| 2026-05-18 | 35.80% | -13.60% | -$1.03 | $16.10 |
| 2026-05-17 | 35.80% | -13.60% | -$1.03 | $16.82 |
| 2026-05-14 | 36.01% | -13.96% | -$1.03 | $17.43 |
| 2026-05-13 | 36.01% | -13.96% | -$1.03 | $17.17 |
| 2026-05-12 | 38.88% | -12.76% | -$0.97 | $16.86 |
| 2026-05-11 | 38.88% | -12.76% | -$0.97 | $17.20 |
| 2026-05-10 | 38.88% | -12.76% | -$0.97 | $16.61 |
| 2026-05-07 | 38.67% | -12.76% | -$0.97 | $17.00 |
| 2026-05-06 | 38.67% | -12.76% | -$0.97 | $17.53 |
| 2026-05-05 | 38.75% | -16.82% | -$1.01 | $18.75 |
| 2026-05-04 | 40.31% | -20.39% | -$1.08 | $14.06 |
| 2026-05-03 | 40.31% | -20.39% | -$1.08 | $13.42 |
Screen Performance
Aggregate stats across all 1781 tickers our top-EPS-revision screen has flagged over the past 71 days.
- Median return since detection
- +3.8%
- % of tickers in the green
- 58%
- Median return on winners
- +18.5%
- Large revisions captured
- 788
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Viridian Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-06-11, Viridian Therapeutics Inc (VRDN) has a next-year EPS growth estimate of 35.80%, based on analyst consensus.
When was the latest EPS estimate revision for VRDN?▾
The most recent revision occurred on 2026-05-17, when analysts adjusted the next-year EPS growth estimate from 36.01% to 35.80%.
What sector and industry does Viridian Therapeutics Inc belong to?▾
Viridian Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. VRDN appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Viridian Therapeutics Inc (VRDN) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports